Rapport Therapeutics, Inc.(RAPP)
$27.02+1.06 (+4.08%)
RAPP
Rapport Therapeutics, Inc. stock forecast
$27.02
At close:+1.06 (+4.08%)
Want to see RAPP full AI Analyst Report?
Rapport Therapeutics, Inc. (RAPP) Stock Forecast & Price Target
173 Followers
RAPP Analyst Ratings
Strong Buy
14Buy0Hold0Sell
Based on 14 analysts giving stock ratings to Rapport Therapeutics, Inc. in the past 3 months
RAPP Stock 12 Month Forecast
Average Price Target
$68.00▲(151.67% Upside)Based on 14 Wall Street analysts offering 12 month price targets for Rapport Therapeutics, Inc. in the last 3 months. The average price target is $68.00 with a high forecast of $91.00 and a low forecast of $47.00. The average price target represents a 151.67% change from the last price of $27.02.
Past 12 Months12 Month ForecastJan2026Oct2026
High$91.00
Average$68.00
Low$47.00
Highest Price TargetHighest$91.00Average Price Target$68.00Lowest Price TargetLowest$47.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Article | |||||||
|---|---|---|---|---|---|---|---|---|
| Justin Walsh | JonesTrading | $82 | buy | 203.48%Upside | Reiterated | 11/12/26 | ||
| Benjamin Burnett | Wells Fargo | $50→$47 | buy | 73.95%Upside | Assigned | 11/05/26 | ||
| Douglas Tsao | H.C. Wainwright | $66→$63 | buy | 133.16%Upside | Assigned | 11/05/26 | ||
| Joon Lee | UBS | $71→$64 | buy | 136.86%Upside | Reiterated | 11/05/26 | ||
| Delma Caiati | Guggenheim | $70→$66 | buy | 144.26%Upside | Reiterated | 11/04/26 | ||
| Salveen Richter | Goldman Sachs | $62→$68 | buy | 151.67%Upside | Reiterated | 10/21/26 | ||
| Tiago Fauth | Raymond James | $75→$86 | buy | 218.28%Upside | Reiterated | 10/20/26 | ||
| Jason Butler | Citizens JMP | $80→$91 | buy | 236.79%Upside | Reiterated | 10/20/26 | ||
| Rudy Li | Wolfe Research | $50 | buy | 85.05%Upside | Initiated | 10/15/26 | ||
| Kambiz Yazdi | BTIG | $75 | buy | 177.57%Upside | Reiterated | 10/01/26 | ||
| Danielle Brill | Truist Financial | ― | buy | ― | Reiterated | 09/23/26 | ||
| Myles Minter | William Blair | ― | buy | ― | Reiterated | 09/23/26 | ||
| Joseph Thome | TD Cowen | ― | buy | ― | Reiterated | 09/22/26 | ||
| Paul Matteis | Stifel Nicolaus | $56 | buy | 107.25%Upside | Reiterated | 09/16/26 | ||
| Marc Goodman | Leerink Partners | $52 | buy | 92.45%Upside | Initiated | 06/24/26 |
| Rating | Article | ||||
|---|---|---|---|---|---|
| Justin WalshJonesTrading | BuyReiterated$82 | 11/12/26 | 203.48%Upside | ||
| Benjamin BurnettWells Fargo | BuyAssigned$50→$47 | 11/05/26 | 73.95%Upside | ||
| Douglas TsaoH.C. Wainwright | BuyAssigned$66→$63 | 11/05/26 | 133.16%Upside | ||
| Joon LeeUBS | BuyReiterated$71→$64 | 11/05/26 | 136.86%Upside | ||
| Delma CaiatiGuggenheim | BuyReiterated$70→$66 | 11/04/26 | 144.26%Upside | ||
| Salveen RichterGoldman Sachs | BuyReiterated$62→$68 | 10/21/26 | 151.67%Upside | ||
| Tiago FauthRaymond James | BuyReiterated$75→$86 | 10/20/26 | 218.28%Upside | ||
| Jason ButlerCitizens JMP | BuyReiterated$80→$91 | 10/20/26 | 236.79%Upside | ||
| Rudy LiWolfe Research | BuyInitiated$50 | 10/15/26 | 85.05%Upside | ||
| Kambiz YazdiBTIG | BuyReiterated$75 | 10/01/26 | 177.57%Upside | ||
| Danielle BrillTruist Financial | BuyReiterated | 09/23/26 | ― | ||
| Myles MinterWilliam Blair | BuyReiterated | 09/23/26 | ― | ||
| Joseph ThomeTD Cowen | BuyReiterated | 09/22/26 | ― | ||
| Paul MatteisStifel Nicolaus | BuyReiterated$56 | 09/16/26 | 107.25%Upside | ||
| Marc GoodmanLeerink Partners | BuyInitiated$52 | 06/24/26 | 92.45%Upside |
Stocks with the Highest Top Analyst Consensus in the General Sector
Best Analysts Covering Rapport Therapeutics, Inc.
3 Months
Success Rate12/18 ratings generated profit
67%
Average Return
+3.58%
Copying Justin Walsh's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +3.58% per trade.
1 Year
Success Rate10/18 ratings generated profit
56%
Average Return
+58.29%
Copying Justin Walsh's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +58.29% per trade.
2 Years
Success Rate10/18 ratings generated profit
56%
Average Return
+34.33%
Copying Justin Walsh's trades and holding each position for 2 Years would result in 55.56% of your transactions generating a profit, with an average return of +34.33% per trade.
RAPP Analyst Recommendation Trends
| Rating | Jul 26 | Aug 26 | Sep 26 | Oct 26 | Nov 26 |
|---|---|---|---|---|---|
| Strong Buy | 5 | 3 | 5 | 15 | 19 |
| Buy | 7 | 15 | 23 | 20 | 9 |
| Hold | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 12 | 18 | 28 | 35 | 28 |
In the current month, RAPP has received 28 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. RAPP average Analyst price target in the past 3 months is 68.00.
RAPP Financial Forecast
High$-0.70
Consensus$-0.87
Low$-1.08
RAPP Earnings Forecast
Next quarter’s earnings estimate for RAPP is -$0.87 with a range of -$1.08 to -$0.70. The previous quarter’s EPS was -$0.84. Its overall industry beat the EPS estimate 50.49% of the time in the past 12 months.
High$100K
Consensus$7K
Low$0.00
RAPP Sales Forecast
Next quarter’s sales forecast for RAPP is $7,000 with a range of $0 to $100.00K. The previous quarter’s sales results were $0. Its overall industry beat sales estimates 63.25% of the time in the past 12 months.
RAPP Stock Forecast FAQ
What is RAPP’s average 12-month price target, according to analysts?
Based on analyst ratings, Rapport Therapeutics, Inc.’s 12-month average price target is $68.00.
What is RAPP’s upside potential, based on the analysts’ average price target?
Rapport Therapeutics, Inc. has 151.67% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RAPP a Buy, Sell or Hold?
Rapport Therapeutics, Inc. has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
What is Rapport Therapeutics, Inc.’s price target?
The average price target for Rapport Therapeutics, Inc. is $68.00. This is based on 14 12-month price targets, issued in the past 3 months. The highest analyst price target is $91.00, the lowest forecast is $47.00. The average price target represents a 151.67% increase from the current price of $27.02.
What do analysts say about Rapport Therapeutics, Inc.?
Rapport Therapeutics, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Street analysts.
How can I buy shares of RAPP?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
